

Alessandro Vitale

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4573279/alessandro-vitale-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

173 papers	4,282 citations	35 h-index	59 g-index
229 ext. papers	5,128 ext. citations	3.7 avg, IF	5.04 L-index

#	Paper	IF	Citations
173	Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment.. <i>Frontiers in Oncology</i> , 2022 , 12, 822507	5.3	0
172	R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation.. <i>JHEP Reports</i> , 2022 , 4, 100445	10.3	0
171	Prognostic Factors for 10-Year Survival in Patients With Hepatocellular Cancer Receiving Liver Transplantation.. <i>Frontiers in Oncology</i> , 2022 , 12, 877107	5.3	0
170	Circulating prostaglandin E: a novel potential prognostic biomarker in patients with hepatocellular carcinoma. <i>Clinical and Experimental Medicine</i> , 2021 , 21, 675-682	4.9	1
169	Liver Resection for Patients with Intermediate Stage Hepatocellular Carcinoma: Beyond Rigid Staging Systems Towards a More Personalized Therapeutic Approach. <i>Journal of Gastrointestinal Surgery</i> , 2021 , 25, 1078-1079	3.3	1
168	Thoracoscopic Ablation of Critically Located Liver Tumors: A Safety and Efficacy Cohort Study. <i>Frontiers in Surgery</i> , 2021 , 8, 626297	2.3	1
167	Influence of Hepatocellular Carcinoma on Platelet Aggregation in Cirrhosis. <i>Cancers</i> , 2021 , 13,	6.6	12
166	Analysis of clinical course of portal vein thrombosis in cirrhosis with hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2021 , 53, S43	3.3	2
165	Liver Transplantation during the COVID-19 pandemic: A quantitative model balancing individual patient benefit against population healthcare needs. <i>Digestive and Liver Disease</i> , 2021 , 53, S44	3.3	78
164	NAFLD: a multi-faceted morbid spectrum with uncertain diagnosis and complicated management. <i>Minerva Surgery</i> , 2021 , 76, 450-466	0.1	0
163	Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications. <i>Cancers</i> , 2021 , 13,	6.6	7
162	Liver transplantation for rare liver diseases and rare indications for liver transplant. <i>Translational Gastroenterology and Hepatology</i> , 2021 , 6, 27	5.2	1
161	Liquid Biopsy in Hepatocellular Carcinoma: Where Are We Now?.. <i>Cancers</i> , 2021 , 13,	6.6	6
160	A Novel Entity Among Vascular Liver Tumors: The First Reported Liver Transplantation. Is It Feasible?. <i>Transplantation Proceedings</i> , 2021 , 53, 1690-1693	1.1	
159	Circulating MicroRNA-21 and MicroRNA-122 as Prognostic Biomarkers in Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization. <i>Biomedicines</i> , 2021 , 9,	4.8	3
158	International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria. <i>JHEP Reports</i> , 2021 , 3, 100331	10.3	4
157	Monofocal hepatocellular carcinoma: How much does size matter?. <i>Liver International</i> , 2021 , 41, 396-407	7.9	7

156	Clinical results of active scanning proton therapy for primary liver tumors. <i>Tumori</i> , 2021 , 107, 71-79	1.7	3
155	Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Liver Cancer</i> , 2021 , 10, 126-136	9.1	3
154	Solid Organ Transplantation During COVID-19 Pandemic: An International Web-based Survey on Resources Allocation. <i>Transplantation Direct</i> , 2021 , 7, e669	2.3	0
153	Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma Patients. <i>Cancers</i> , 2021 , 13,	6.6	4
152	Colon Rectal Liver Metastases: The Role of the Liver Transplantation in the Era of the Transplant Oncology and Precision Medicine. <i>Frontiers in Surgery</i> , 2021 , 8, 693387	2.3	1
151	Evaluation of the Intention-to-Treat Benefit of Living Donation in Patients With Hepatocellular Carcinoma Awaiting a Liver Transplant. <i>JAMA Surgery</i> , 2021 , 156, e213112	5.4	4
150	Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation. <i>Cancers</i> , 2021 , 13,	6.6	2
149	Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival. <i>Digestive and Liver Disease</i> , 2021 ,	3.3	2
148	Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database.. <i>Gut</i> , 2021 ,	19.2	8
147	Development and Validation of a Comprehensive Model to Estimate Early Allograft Failure Among Patients Requiring Early Liver Retransplant. <i>JAMA Surgery</i> , 2020 , 155, e204095	5.4	27
146	Changing indications for liver transplant: slow decline of hepatitis viruses in Italy. <i>Infectious Diseases</i> , 2020 , 52, 557-562	3.1	0
145	Sorafenib treatment has the potential to downstage advanced hepatocellular carcinoma before liver resection. <i>Personalized Medicine</i> , 2020 , 17, 83-87	2.2	8
144	Identification of an Upper Limit of Tumor Burden for Downstaging in Candidates with Hepatocellular Cancer Waiting for Liver Transplantation: A West-East Collaborative Effort. <i>Cancers</i> , 2020 , 12,	6.6	8
143	Treatment of Hepatocellular Carcinoma in the Precision Medicine Era: From Treatment Stage Migration to Therapeutic Hierarchy. <i>Hepatology</i> , 2020 , 72, 2206-2218	11.2	49
142	SCCA-IgM in hepatocellular carcinoma patients treated with transarterial chemoembolization: gender-related differences. <i>Biomarkers in Medicine</i> , 2020 , 14, 855-867	2.3	2
141	A 2020 update on liver transplant for hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020 , 14, 885-900	4.2	4
140	Global management of a common, underrated surgical task during the COVID-19 pandemic: Gallstone disease - An international survey. <i>Annals of Medicine and Surgery</i> , 2020 , 57, 95-102	2	8
139	Charting the Path Forward for Risk Prediction in Liver Transplant for Hepatocellular Carcinoma: International Validation of HALTHCC Among 4,089 Patients. <i>Hepatology</i> , 2020 , 71, 569-582	11.2	17

138	Protein kinase C inhibitors override ZEB1-induced chemoresistance in HCC. <i>Cell Death and Disease</i> , 2019 , 10, 703	9.8	18
137	Risk Factors for Early Mortality in Liver Transplant Patients. <i>Transplantation Proceedings</i> , 2019 , 51, 179-183		5
136	A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2019 , 31, 34-42	2.2	34
135	The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study. <i>Liver International</i> , 2019 , 39, 1478-1489	7.9	27
134	Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis. <i>Expert Opinion on Drug Safety</i> , 2019 , 18, 603-610	4.1	10
133	The Intention-to-Treat Effect of Bridging Treatments in the Setting of Milan Criteria-In Patients Waiting for Liver Transplantation. <i>Liver Transplantation</i> , 2019 , 25, 1023-1033	4.5	10
132	Outcome of a First Episode of Bacterial Infection in Candidates for Liver Transplantation. <i>Liver Transplantation</i> , 2019 , 25, 1187-1197	4.5	4
131	Videolaparoscopic microwave ablation in patients with HCC at a European high-volume center: Results of 815 procedures. <i>Journal of Surgical Oncology</i> , 2019 , 120, 956-965	2.8	9
130	Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics. <i>Cancers</i> , 2019 , 11,	6.6	13
129	Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice. <i>Cancers</i> , 2019 , 11,	6.6	25
128	Very Early Introduction of Everolimus in De Novo Liver Transplantation: Results of a Multicenter, Prospective, Randomized Trial. <i>Liver Transplantation</i> , 2019 , 25, 242-251	4.5	13
127	Reply. <i>Hepatology</i> , 2019 , 69, 465-466	11.2	
126	Reply. <i>Hepatology</i> , 2018 , 67, 1639-1640	11.2	
125	Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group. <i>Journal of Gastrointestinal Surgery</i> , 2018 , 22, 859-871	3.3	17
124	Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients. <i>Digestive and Liver Disease</i> , 2018 , 50, 156-162	3.3	4
123	Which Is the True Role of Bridging Therapies for HCC Patients Waiting for Liver Transplantation?. <i>Annals of Surgery</i> , 2018 , 268, e56-e57	7.8	1
122	Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study. <i>Hepatology</i> , 2018 , 68, 1232-1244	11.2	15
121	Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis. <i>Digestive and Liver Disease</i> , 2018 , 50, 1105-1114	3.3	26

120	New trends and perspectives in hepatobiliary surgery: preface. <i>Translational Gastroenterology and Hepatology</i> , 2018 , 3, 99	5.2	
119	Resection for hepatocellular cancer: overpassing old barriers. <i>Translational Gastroenterology and Hepatology</i> , 2018 , 3, 64	5.2	5
118	Transplantation for hepatocellular cancer: pushing to the limits?. <i>Translational Gastroenterology and Hepatology</i> , 2018 , 3, 61	5.2	2
117	Liver Resection for Breast Cancer Liver Metastases: A Cost-utility Analysis. <i>Annals of Surgery</i> , 2017 , 265, 792-799	7.8	25
116	Serum alkaline phosphatase, a risk factor for non-alcoholic fatty liver, but only for women in their 30s and 40s: evidence from a large cohort study. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017 , 11, 269-276	4.2	8
115	The NAFL Risk Score: A simple scoring model to predict 4-y risk for non-alcoholic fatty liver. <i>Clinica Chimica Acta</i> , 2017 , 468, 17-24	6.2	2
114	Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2017 , 49, 440-445	3.3	45
113	Management and prognosis of hepatocellular carcinoma in the elderly: Results of an in-field multicenter cohort study. <i>Liver International</i> , 2017 , 37, 1184-1192	7.9	12
112	Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. <i>Journal of Hepatology</i> , 2017 , 66, 552-559	13.4	110
111	Liver Retransplantation for Hepatic Abscess Due to Hepatic Artery Thrombosis: A Case Report. <i>Transplantation Proceedings</i> , 2017 , 49, 736-739	1.1	
110	Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals. <i>Liver Transplantation</i> , 2017 , 23, 1103-1112	4.5	37
109	Liver transplantation for hepatocellular carcinoma through the lens of transplant benefit. <i>Hepatology</i> , 2017 , 65, 1741-1748	11.2	22
108	Transarterial Chemoembolization with Small Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: Experience from a Cohort of 421 Patients at an Italian Center. <i>Journal of Vascular and Interventional Radiology</i> , 2017 , 28, 1495-1502	2.4	30
107	Reply. <i>Liver Transplantation</i> , 2017 , 23, 1630-1631	4.5	
106	Selection of patients with hepatocellular cancer: a difficult balancing between equity, utility, and benefit. <i>Translational Gastroenterology and Hepatology</i> , 2017 , 2, 75	5.2	6
105	Intention-to-treat survival benefit of liver transplantation in patients with hepatocellular cancer. <i>Hepatology</i> , 2017 , 66, 1910-1919	11.2	65
104	Liver radiofrequency ablation as emergency treatment for a ruptured hepatocellular carcinoma: a case report. <i>Journal of Medical Case Reports</i> , 2017 , 11, 54	1.2	4
103	Consensus conference on TIPS management: Techniques, indications, contraindications. <i>Digestive and Liver Disease</i> , 2017 , 49, 121-137	3.3	60

102	Personalized treatment of patients with very early hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017 , 66, 412-423	13.4	75
101	Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. <i>Digestive and Liver Disease</i> , 2016 , 48, 455-467	3.3	41
100	Estimation of Liver Transplant Related Survival Benefit: the Devil Is in The Details. <i>Gastroenterology</i> , 2016 , 150, 534-5	13.3	2
99	Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2016 , 111, 70-7	0.7	42
98	Differential timing of oxidative DNA damage and telomere shortening in hepatitis C and B virus-related liver carcinogenesis. <i>Translational Research</i> , 2016 , 168, 122-133	11	12
97	Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma. <i>PLoS Medicine</i> , 2016 , 13, e1002006	11.6	81
96	Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation. <i>World Journal of Gastroenterology</i> , 2016 , 22, 232-52	5.6	31
95	A multi-institutional analysis of elderly patients undergoing a liver resection for intrahepatic cholangiocarcinoma. <i>Journal of Surgical Oncology</i> , 2016 , 113, 420-6	2.8	29
94	Defining the possible therapeutic benefit of lymphadenectomy among patients undergoing hepatic resection for intrahepatic cholangiocarcinoma. <i>Journal of Surgical Oncology</i> , 2016 , 113, 685-91	2.8	35
93	Net health benefit of hepatic resection versus intraarterial therapies for neuroendocrine liver metastases: A Markov decision model. <i>Surgery</i> , 2015 , 158, 339-48	3.6	20
92	Liver Resection for Advanced Intrahepatic Cholangiocarcinoma: A Cost-Utility Analysis. <i>World Journal of Surgery</i> , 2015 , 39, 2500-9	3.3	14
91	Management of hepatitis C infection before and after liver transplantation. <i>World Journal of Gastroenterology</i> , 2015 , 21, 4447-56	5.6	12
90	The relative net health benefit of liver resection, ablation, and transplantation for early hepatocellular carcinoma. <i>World Journal of Surgery</i> , 2015 , 39, 1474-84	3.3	30
89	Hepatic Resection for Disappearing Liver Metastasis: a Cost-Utility Analysis. <i>Journal of Gastrointestinal Surgery</i> , 2015 , 19, 1668-75	3.3	8
88	Survival Benefit of Liver Transplantation Versus Resection for Hepatocellular Carcinoma: Impact of MELD Score. <i>Annals of Surgical Oncology</i> , 2015 , 22, 1901-7	3.1	35
87	Can hepatic resection provide a long-term cure for patients with intrahepatic cholangiocarcinoma?. <i>Cancer</i> , 2015 , 121, 3998-4006	6.4	91
86	Urgency, utility, and time horizon of transplant benefit. <i>Liver Transplantation</i> , 2015 , 21, 565-6	4.5	5
85	Age and equity in liver transplantation: An organ allocation model. <i>Liver Transplantation</i> , 2015 , 21, 1241-2	4.5	21

84	Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation. <i>Transplant International</i> , 2015 , 28, 1055-65	3	7
83	Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor. <i>Liver Transplantation</i> , 2015 , 21, 1250-8	4.5	9
82	When to perform hepatic resection for intermediate-stage hepatocellular carcinoma. <i>Hepatology</i> , 2015 , 61, 905-14	11.2	55
81	Readmission After Liver Resection for Intrahepatic Cholangiocarcinoma: a Multi-Institutional Analysis. <i>Journal of Gastrointestinal Surgery</i> , 2015 , 19, 1334-41	3.3	11
80	BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group. <i>Liver International</i> , 2015 , 35, 223-31	7.9	30
79	Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study. <i>Journal of Hepatology</i> , 2015 , 62, 617-24	13.4	129
78	SERPINB3 is associated with TGF- β and cytoplasmic E-cadherin expression in hepatocellular carcinomas with poor prognosis. <i>British Journal of Cancer</i> , 2014 , 110, 2708-15	8.7	44
77	Survival benefit of transplantation for recurrence of hepatocellular carcinoma after liver resection. <i>Transplantation Proceedings</i> , 2014 , 46, 2287-9	1.1	5
76	A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the liver match study. <i>Digestive and Liver Disease</i> , 2014 , 46, 340-7	3.3	12
75	A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list. <i>Journal of Hepatology</i> , 2014 , 60, 290-7	13.4	69
74	Is resectable hepatocellular carcinoma a contraindication to liver transplantation? A novel decision model based on "number of patients needed to transplant" as measure of transplant benefit. <i>Journal of Hepatology</i> , 2014 , 60, 1165-71	13.4	38
73	P915 PREDICTION OF RECURRENCE AFTER LIVER TRANSPLANTATION FOR HCC: VALIDATION OF THE AFP MODEL IN AN ITALIAN COHORT. <i>Journal of Hepatology</i> , 2014 , 60, S380	13.4	2
72	Laparoscopic microwave ablation in patients with hepatocellular carcinoma: a prospective cohort study. <i>Hpb</i> , 2014 , 16, 979-86	3.8	22
71	Can liver transplantation provide the statistical cure?. <i>Liver Transplantation</i> , 2014 , 20, 210-7	4.5	9
70	Sorafenib use in the transplant setting. <i>Liver Transplantation</i> , 2014 , 20, 1021-8	4.5	10
69	Prognostic prediction and identification of candidates for salvage liver transplantation among patients with early hepatocellular carcinoma. <i>Liver Transplantation</i> , 2014 , 20, 1150-1	4.5	2
68	Liver transplantation in children with congenital cardiac defects: a case report and a short literature review. <i>Transplantation Proceedings</i> , 2013 , 45, 2769-73	1.1	2
67	Circulating free DNA in the progression of liver damage to hepatocellular carcinoma. <i>Hepatology International</i> , 2013 , 7, 1050-7	8.8	52

66	108 A NOVEL MODEL OF PRIORITY ASSESSMENT FOR PATIENTS WITH AND WITHOUT HEPATOCELLULAR CARCINOMA ON A COMMON LIVER TRANSPLANT WAITING LIST: A MULTICENTRE, COHORT STUDY. <i>Journal of Hepatology</i> , 2013 , 58, S48	13.4	2
65	Model for end-stage liver disease-sodium and survival benefit in liver transplantation. <i>Transplant International</i> , 2013 , 26, 138-44	3	5
64	Use of N-acetylcysteine during liver procurement: a prospective randomized controlled study. <i>Liver Transplantation</i> , 2013 , 19, 135-44	4.5	42
63	Who fares worse after liver transplantation? Impact of donor and recipient variables on outcome: data from a prospective study. <i>Transplantation</i> , 2013 , 95, 1528-34	1.8	15
62	Laparoscopic ablation of hepatocellular carcinoma in cirrhotic patients unsuitable for liver resection or percutaneous treatment: a cohort study. <i>PLoS ONE</i> , 2013 , 8, e57249	3.7	21
61	Transplant benefit for patients with hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2013 , 19, 9183-8	5.6	16
60	Liver autotransplantation for the treatment of unresectable hepatic metastasis: an uncommon indication-a case report. <i>Transplantation Proceedings</i> , 2012 , 44, 1930-3	1.1	21
59	Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation?. <i>Transplantation Proceedings</i> , 2012 , 44, 1989-91	1.1	24
58	Skin cancer and other cutaneous disorders in liver transplant recipients. <i>Acta Dermato-Venereologica</i> , 2012 , 92, 411-5	2.2	25
57	Sorafenib as bridging therapy in patients with intermediate hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e14563-e14563	2.2	
56	Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. <i>Lancet Oncology</i> , 2011 , 12, 654-62	21.7	114
55	Antiviral treatment for HCV recurrence after liver transplantation: when, how much and for how long?. <i>Future Virology</i> , 2011 , 6, 1179-1186	2.4	2
54	A novel approach to severe acute pancreatitis in sequential liver-kidney transplantation: the first report on the application of VAC therapy. <i>Transplant International</i> , 2011 , 24, e23-7	3	4
53	Balancing donor and recipient risk factors in liver transplantation: the value of D-MELD with particular reference to HCV recipients. <i>American Journal of Transplantation</i> , 2011 , 11, 2724-36	8.7	77
52	Donor-Model for End-Stage Liver Disease and donor-recipient matching in liver transplantation. <i>Transplantation Proceedings</i> , 2011 , 43, 974-6	1.1	13
51	Neoadjuvant therapy protocol and liver transplantation in combination with pancreatoduodenectomy for the treatment of hilar cholangiocarcinoma occurring in a case of primary sclerosing cholangitis: case report with a more than 8-year disease-free survival. <i>Transplantation Proceedings</i> , 2011 , 43, 1187-9	1.1	4
50	Risk factors in liver retransplantation: a single-center experience. <i>Transplantation Proceedings</i> , 2011 , 43, 1110-3	1.1	25
49	Intensive care unit admission of decompensated cirrhotic patients: prognostic scoring systems. <i>Transplantation Proceedings</i> , 2011 , 43, 1079-84	1.1	8

48	Microwave thermal ablation for hepatocarcinoma: six liver transplantation cases. <i>Transplantation Proceedings</i> , 2011 , 43, 1091-4	1.1	22
47	Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation: a randomized, open-label trial. <i>Liver Transplantation</i> , 2011 , 17, 167-77	4.5	47
46	Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study. <i>Cancer</i> , 2011 , 117, 125-33	6.4	34
45	Molecular refinement of clinical staging in hepatocellular carcinoma patients evaluated for potentially curative therapies. <i>PLoS ONE</i> , 2011 , 6, e23093	3.7	4
44	Comparison of de novo tumours after liver transplantation with incidence rates from Italian cancer registries. <i>Digestive and Liver Disease</i> , 2010 , 42, 55-60	3.3	57
43	The survival benefit of liver transplantation in hepatocellular carcinoma patients. <i>Digestive and Liver Disease</i> , 2010 , 42, 642-9	3.3	32
42	Estimation of the harm to the waiting list as a crucial factor in the selection of patients with hepatocellular carcinoma for liver transplantation. <i>Transplantation Proceedings</i> , 2010 , 42, 1194-6	1.1	16
41	Liver resection associated with mini porto-caval shunt as salvage treatment in patients with progression of hepatocellular carcinoma before liver transplantation: a case report. <i>Transplantation Proceedings</i> , 2010 , 42, 1378-80	1.1	2
40	Fibrosis progression and the pros and cons of antiviral therapy for hepatitis C virus recurrence after liver transplantation: a review. <i>Transplantation Proceedings</i> , 2010 , 42, 2223-5	1.1	9
39	Sexual dysfunction in chronic liver disease: is liver transplantation an effective cure?. <i>Transplantation</i> , 2010 , 89, 1425-9	1.8	36
38	Response to therapy as a criterion for awarding priority to patients with hepatocellular carcinoma awaiting liver transplantation. <i>Annals of Surgical Oncology</i> , 2010 , 17, 2290-302	3.1	53
37	Harm and benefits of primary liver resection and salvage transplantation for hepatocellular carcinoma. <i>American Journal of Transplantation</i> , 2010 , 10, 619-27	8.7	64
36	Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. <i>Hepatology</i> , 2010 , 51, 165-73	11.2	75
35	Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. <i>Liver Transplantation</i> , 2009 , 15, 1278-87	4.5	90
34	Prospective validation of a new priority allocation model for liver transplant candidates: an interim analysis. <i>Transplantation Proceedings</i> , 2009 , 41, 1092-5	1.1	11
33	Validation of the BCLC prognostic system in surgical hepatocellular cancer patients. <i>Transplantation Proceedings</i> , 2009 , 41, 1260-3	1.1	35
32	Alcohol abuse and de novo tumors in liver transplantation. <i>Transplantation Proceedings</i> , 2009 , 41, 1310-2	1.1	12
31	De novo tumors are a major cause of late mortality after orthotopic liver transplantation. <i>Transplantation Proceedings</i> , 2009 , 41, 1303-5	1.1	41

30	Progression of hepatocellular carcinoma before liver transplantation: dropout or liver transplantation?. <i>Transplantation Proceedings</i> , 2009 , 41, 1264-7	1.1	18
29	Prognostic evaluation of the donor risk index among a prospective cohort of Italian patients undergoing liver transplantation. <i>Transplantation Proceedings</i> , 2009 , 41, 1096-8	1.1	11
28	Benefit and harm of deceased- or living-donor liver transplantation for hepatocellular carcinoma. <i>Digestive and Liver Disease Supplements</i> , 2009 , 3, 88-92		
27	Liver transplantation for hepatocellular carcinoma: Are the Milan criteria still valid?. <i>European Journal of Surgical Oncology</i> , 2008 , 34, 256-62	3.6	46
26	Reply: The easiest way to improve the outcome of suboptimal liver grafts. <i>Liver Transplantation</i> , 2008 , 14, 906-907	4.5	0
25	Liver transplantation using suboptimal grafts: impact of donor harvesting technique. <i>Liver Transplantation</i> , 2007 , 13, 1444-50	4.5	24
24	Partial hepatectomy as first-line treatment for patients with hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2007 , 95, 213-20	2.8	22
23	Intention-to-treat analysis of liver transplantation in selected, aggressively treated HCC patients exceeding the Milan criteria. <i>American Journal of Transplantation</i> , 2007 , 7, 972-81	8.7	100
22	Alcohol- and substance-dependent subjects: the correlated factors in qualifying for liver transplantation. <i>Transplantation Proceedings</i> , 2007 , 39, 1861-3	1.1	2
21	Hepatitis C virus-related cirrhosis as a significant mortality factor in intention-to-treat analysis in liver transplantation. <i>Transplantation Proceedings</i> , 2007 , 39, 1901-3	1.1	9
20	Long-term results of liver transplantation for hepatocellular carcinoma: an update of the University of Padova experience. <i>Transplantation Proceedings</i> , 2007 , 39, 1892-4	1.1	7
19	Prognostic impact of model for end-stage liver disease score in patients undergoing liver transplantation with suboptimal livers. <i>Transplantation Proceedings</i> , 2007 , 39, 1907-9	1.1	7
18	Combined liver and kidney transplantation: analysis of Padova experience. <i>Transplantation Proceedings</i> , 2007 , 39, 1933-5	1.1	8
17	Pediatric liver transplantation: the University of Padua experience. <i>Transplantation Proceedings</i> , 2007 , 39, 1939-41	1.1	4
16	Prospective validation of the Barcelona Clinic Liver Cancer staging system. <i>Journal of Hepatology</i> , 2006 , 44, 723-31	13.4	323
15	Syngeneic living-donor liver transplantation for hemangioendothelioma: a clinical model for studying liver regeneration. <i>American Journal of Transplantation</i> , 2005 , 5, 2309-14	8.7	4
14	Isoniazid-related fulminant hepatic failure in a child: assessment of the native liverWearly regeneration after auxiliary partial orthotopic liver transplantation. <i>Transplant International</i> , 2005 , 17, 713-6	3	10
13	Multimodal therapy before liver transplantation for hepatocellular carcinoma. <i>Hepatology Research</i> , 2005 , 31, 112-5	5.1	11

12	Early surgery for the treatment of toxic megacolon. <i>Digestion</i> , 2005 , 72, 146-9	3.6	12
11	Role of blood AFP mRNA and tumor grade in the preoperative prognostic evaluation of patients with hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2005 , 11, 6920-5	5.6	17
10	Isoniazid-related fulminant hepatic failure in a child: assessment of the native liver's early regeneration after auxiliary partial orthotopic liver transplantation. <i>Transplant International</i> , 2004 , 17, 713-716	3	2
9	Growth hormone/insulin-like growth factor 1 axis recovery after liver transplantation: a preliminary prospective study. <i>Liver Transplantation</i> , 2004 , 10, 692-8	4.5	13
8	Clinical significance of alpha-fetoprotein mRNA in blood of patients with hepatocellular carcinoma. <i>Clinica Chimica Acta</i> , 2004 , 347, 129-38	6.2	29
7	The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available?. <i>Journal of Hepatology</i> , 2004 , 40, 124-31	13.4	138
6	Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. <i>Annals of Surgery</i> , 2004 , 239, 150-9	7.8	247
5	A multicenter pilot prospective study comparing Celsior and University of Wisconsin preserving solutions for use in liver transplantation. <i>Liver Transplantation</i> , 2003 , 9, 814-21	4.5	75
4	Liver transplantation for the management of hepatoblastoma. <i>Transplantation Proceedings</i> , 2003 , 35, 2983-5	1.1	20
3	Adjuvant chemotherapy for transplanted hepatocellular carcinoma patients: impact on survival or HCV recurrence timing. <i>Transplantation Proceedings</i> , 2003 , 35, 2991-4	1.1	16
2	Extreme marginal donor: severe hypothermia as a rare preservation condition for explantable organs--a case report. <i>Transplantation Proceedings</i> , 2003 , 35, 1282-4	1.1	6
1	Multimodal approach and its impact on survival for patients with hepatocellular carcinoma. <i>Anticancer Research</i> , 2003 , 23, 4047-53	2.3	4